# Hoffmann-La Roche: Phase 3 study closed enrollment, 672 enrolled (Diabetic Macular Edema)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME |
| NCT ID | NCT04108156 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Diabetic Macular Edema |
| Intervention types | drug |
| Target enrollment | 672 |
| Site countries | United States |
| Posted | 2019-09-30 |
| Planned start | 2019-09-30 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-08 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 672 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04108156). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.